This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Warren, K. E. Articles by Balis, F. M. Search for Related Content PubMed PubMed Citation Articles by Warren, K. E. Articles by Balis, F. M. Social Bookmarking                            What's this?

Proton Magnetic Resonance Spectroscopic Imaging in Children With Recurrent Primary Brain Tumors

From the Pediatric Oncology Branch, National Cancer Institute; National Institute of Neurological Disorders and Stroke, and Laboratory of Diagnostic Radiology Research, National Institutes of Health, Bethesda, MD.

Address reprint requests to Katherine E. Warren, MD, Pediatric Oncology Branch, NCI, Bldg 10, Rm 13N240, 10 Center Dr, MSC 1928, Bethesda, MD 20892-1928; email warrenk{at}exchange.nih.gov

PURPOSE: Proton magnetic resonance spectroscopic imaging (¹H-MRSI) is a noninvasive technique for spatial characterization of biochemical markers in tissues. We measured the relative tumor concentrations of these biochemical markers in children with recurrent brain tumors and evaluated their potential prognostic significance.

PATIENTS AND METHODS: ¹H-MRSI was performed on 27 children with recurrent primary brain tumors referred to our institution for investigational drug trials. Diagnoses included high-grade glioma (n = 10), brainstem glioma (n = 7), medulloblastoma/peripheral neuroectodermal tumor (n = 6), ependymoma (n = 3), and pineal germinoma (n = 1). ¹H-MRSI was performed on 1.5-T magnetic resonance imagers before treatment. The concentrations of choline (Cho) and N-acetyl-aspartate (NAA) in the tumor and normal brain were quantified using a multislice multivoxel method, and the maximum Cho:NAA ratio was determined for each patient’s tumor.

RESULTS: The maximum Cho:NAA ratio ranged from 1.1 to 13.2 (median, 4.5); the Cho:NAA ratio in areas of normal-appearing brain tissue was less than 1.0. The maximum Cho:NAA ratio for each histologic subtype varied considerably; approximately equal numbers of patients within each tumor type had maximum Cho:NAA ratios above and below the median. Patients with a maximum Cho:NAA ratio greater than 4.5 had a median survival of 22 weeks, and all 13 patients died by 63 weeks. Patients with a Cho:NAA ratio less than or equal to 4.5 had a projected survival of more than 50% at 63 weeks. The difference was statistically significant (P = .0067, log-rank test).

CONCLUSION: The maximum tumor Cho:NAA ratio seems to be predictive of outcome in children with recurrent primary brain tumors and should be evaluated as a prognostic indicator in newly diagnosed childhood brain tumors.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				L.-G. Vezina Imaging of Central Nervous System Tumors in Children: Advances and Limitations J Child Neurol, October 1, 2008; 23(10): 1128 - 1135. [Abstract] [PDF]

				M. Lindskog, C. Spenger, J. Jarvet, A. Graslund, and P. Kogner Predicting Resistance or Response to Chemotherapy by Proton Magnetic Resonance Spectroscopy in Neuroblastoma J Natl Cancer Inst, October 6, 2004; 96(19): 1457 - 1466. [Abstract] [Full Text] [PDF]

				K. E. Warren NMR Spectroscopy and Pediatric Brain Tumors Oncologist, June 1, 2004; 9(3): 312 - 318. [Abstract] [Full Text] [PDF]